kvd824
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 12, 2019 (NCT05178355)
Timeline
Indications
Mechanism of action
- Kallikrein 1INHIBITOR
Kallikrein 1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05055258 | Phase 2 | Sep 27, 2021 | KalVista Pharmaceuticals, Ltd. |
| NCT05118958 | Phase 1 | May 19, 2020 | KalVista Pharmaceuticals, Ltd. |
| NCT05178355 | Phase 1 | Feb 12, 2019 | KalVista Pharmaceuticals, Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Ltd. | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1